Items tagged with Access
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows (post)
HIV, hepatitis B and C and TB can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported at the 9th International AIDS Society Conference on HIV Science in Paris.
US govt supports introduction of new TB drug to PNG (post)
The United States Agency for International Development (USAID) is working with partner organisations to introduce a new drug into Papua New Guinea called bedaquiline, the first new drug for tuberculosis in over 45 years.
How patients navigate the diagnostic ecosystem in a fragmented health system: a qualitative study from India (post)
Abstract
Treatment initiation among persons diagnosed with drug-resistant TB in Johannesburg, South Africa (post)
Abstract
Mylan gets DCGI approval to market anti-TB drug delamanid (post)
Mylan’s TB drug delamanid will be limited to those patients who have stopped responding to most of first and second line of treatment
Otsuka and Mylan announce license agreement to commercialize delamanid (Deltyba™) for MDR-TB in high-burden countries (post)
TOKYO, HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2017 -- Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Mylan N.V. (NASDAQ, TASE: MYL) have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in low- and middle-income countries. Delamanid was discovered and developed, and is currently marketed by Otsuka under the brand name Deltyba™.
India's battle with TB continues to take lives, and treatment is still hard to manage (post)
When her 1-year old son became very sick, Mona Balani consulted multiple government and private doctors.
Better data on fake drugs needed to fight the scourge (post)
The problem of fake medicines is a big one. But precisely how big?
WHO prequalifies key treatment for children with TB (post)
01 September 2017 - WHO has just prequalified a two-pills-in-one paediatric medicine that is critical for the continuation phase of the six-month treatment required to cure tuberculosis (TB). The medicine – rifampicin 75mg + isoniazid 50mg – is a fixed dose combination (FDC) tablet manufactured by Macleods Pharmaceuticals Limited. WHO medicines prequalification activities are partly funded by the Bill & Melinda Gates Foundation and by Unitaid.
The link between TB, migration, human rights and ethics (post)
Oliver is a 27 year old male who decides to migrate to Europe after experiencing violence, conflict and uncertainty in his home country in sub-Saharan African. It takes him two months to travel to a North African country where he lives in a warehouse with 25 other migrants seeking to earn enough money to pay smugglers to get them across the Mediterranean to southern Europe. There, on top of experiencing food insecurity and poor sanitation, Oliver develops a persistent cough and loses weight, which he attributes to his arduous journey and difficulties since then. He finally saves enough money to make the treacherous trip across the Mediterranean.
Page 30 of 83 · Total posts: 0
←First 29 30 31 Last→